Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
EGFR
antibody drug conjugate
depatuxizumab mafodotin
glioblastoma
phase III
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
14 02 2023
14 02 2023
Historique:
pubmed:
19
7
2022
medline:
16
2
2023
entrez:
18
7
2022
Statut:
ppublish
Résumé
Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody-drug conjugate comprised of a monoclonal antibody that binds activated EGFR (overexpressed wild-type and EGFRvIII-mutant) linked to a microtubule-inhibitor toxin in EGFR-amp GBMs. In this phase III trial, adults with centrally confirmed, EGFR-amp newly diagnosed GBM were randomized 1:1 to radiotherapy, temozolomide, and depatux-m/placebo. Corneal epitheliopathy was treated with a combination of protocol-specified prophylactic and supportive measures. There was 85% power to detect a hazard ratio (HR) ≤0.75 for overall survival (OS) at a 2.5% 1-sided significance level (ie traditional two-sided p ≤ 0.05) by log-rank testing. There were 639 randomized patients (median age 60, range 22-84; 62% men). Prespecified interim analysis found no improvement in OS for depatux-m over placebo (median 18.9 vs. 18.7 months, HR 1.02, 95% CI 0.82-1.26, 1-sided p = 0.63). Progression-free survival was longer for depatux-m than placebo (median 8.0 vs. 6.3 months; HR 0.84, 95% confidence interval [CI] 0.70-1.01, p = 0.029), particularly among those with EGFRvIII-mutant (median 8.3 vs. 5.9 months, HR 0.72, 95% CI 0.56-0.93, 1-sided p = 0.002) or MGMT unmethylated (HR 0.77, 95% CI 0.61-0.97; 1-sided p = 0.012) tumors but without an OS improvement. Corneal epitheliopathy occurred in 94% of depatux-m-treated patients (61% grade 3-4), causing 12% to discontinue. Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM. No new important safety risks were identified.
Sections du résumé
BACKGROUND
Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody-drug conjugate comprised of a monoclonal antibody that binds activated EGFR (overexpressed wild-type and EGFRvIII-mutant) linked to a microtubule-inhibitor toxin in EGFR-amp GBMs.
METHODS
In this phase III trial, adults with centrally confirmed, EGFR-amp newly diagnosed GBM were randomized 1:1 to radiotherapy, temozolomide, and depatux-m/placebo. Corneal epitheliopathy was treated with a combination of protocol-specified prophylactic and supportive measures. There was 85% power to detect a hazard ratio (HR) ≤0.75 for overall survival (OS) at a 2.5% 1-sided significance level (ie traditional two-sided p ≤ 0.05) by log-rank testing.
RESULTS
There were 639 randomized patients (median age 60, range 22-84; 62% men). Prespecified interim analysis found no improvement in OS for depatux-m over placebo (median 18.9 vs. 18.7 months, HR 1.02, 95% CI 0.82-1.26, 1-sided p = 0.63). Progression-free survival was longer for depatux-m than placebo (median 8.0 vs. 6.3 months; HR 0.84, 95% confidence interval [CI] 0.70-1.01, p = 0.029), particularly among those with EGFRvIII-mutant (median 8.3 vs. 5.9 months, HR 0.72, 95% CI 0.56-0.93, 1-sided p = 0.002) or MGMT unmethylated (HR 0.77, 95% CI 0.61-0.97; 1-sided p = 0.012) tumors but without an OS improvement. Corneal epitheliopathy occurred in 94% of depatux-m-treated patients (61% grade 3-4), causing 12% to discontinue.
CONCLUSIONS
Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM. No new important safety risks were identified.
Identifiants
pubmed: 35849035
pii: 6645128
doi: 10.1093/neuonc/noac173
pmc: PMC9925712
doi:
Substances chimiques
depatuxizumab mafodotin
F3R7A4P04N
Antibodies, Monoclonal, Humanized
0
Temozolomide
YF1K15M17Y
ErbB Receptors
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-350Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Références
Pharm Stat. 2016 Sep;15(5):412-9
pubmed: 27353855
Nature. 1985 Jan 10-18;313(5998):144-7
pubmed: 2981413
Neoplasia. 2007 Dec;9(12):1099-110
pubmed: 18084617
FEBS J. 2013 Nov;280(21):5350-70
pubmed: 23777544
Neuro Oncol. 2021 Dec 1;23(12):2042-2053
pubmed: 34050676
Neuro Oncol. 2017 Jul 01;19(7):965-975
pubmed: 28039367
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Mol Cancer Ther. 2018 Apr;17(4):795-805
pubmed: 29483208
J Clin Oncol. 2004 Jan 1;22(1):157-65
pubmed: 14701778
Pharm Stat. 2020 Sep;19(5):733-735
pubmed: 32185868
Neuro Oncol. 2020 May 15;22(5):684-693
pubmed: 31747009
Neurooncol Adv. 2021 Aug 03;3(1):vdab102
pubmed: 34549181
J Clin Oncol. 2013 Nov 10;31(32):4076-84
pubmed: 24101048
Ther Adv Med Oncol. 2020 May 27;12:1758835920907543
pubmed: 32550861
J Neurooncol. 2006 Oct;80(1):27-35
pubmed: 16598415
J Natl Cancer Inst. 2019 Jun 1;111(6):538-549
pubmed: 30859213
Neuro Oncol. 2018 May 18;20(6):838-847
pubmed: 29077941
Invest New Drugs. 2015 Jun;33(3):671-8
pubmed: 25895099
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6
pubmed: 17360479
Cochrane Database Syst Rev. 2020 May 12;5:CD013238
pubmed: 32395825
Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217
pubmed: 29075855
Stat Med. 2010 Jan 30;29(2):219-28
pubmed: 19827011
Bioconjug Chem. 2008 Oct;19(10):1960-3
pubmed: 18803412
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
pubmed: 15329413
Cell Biol Int. 2020 Jun;44(6):1267-1282
pubmed: 32162758
Clin Cancer Res. 2019 Jun 1;25(11):3259-3265
pubmed: 30796037
J Clin Oncol. 2020 Apr 1;38(10):1019-1029
pubmed: 32058845
Neuro Oncol. 2011 Jun;13(6):660-8
pubmed: 21558074
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10009-10018
pubmed: 31028138
Ann Oncol. 2009 Sep;20(9):1596-1603
pubmed: 19491283
Neuro Oncol. 2019 Jan 1;21(1):106-114
pubmed: 29982805
Cancer Res. 2012 Jun 15;72(12):2924-30
pubmed: 22659454
J Chronic Dis. 1974 Sep;27(7-8):365-75
pubmed: 4612056
Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):639-44
pubmed: 12515857
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
J Clin Oncol. 2013 Nov 10;31(32):4085-91
pubmed: 24101040
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Neurooncol Adv. 2019 Dec 09;2(1):vdz051
pubmed: 32642719
Cancer. 2011 Jul 15;117(14):3222-8
pubmed: 21264841
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Hybridoma. 2001 Apr;20(2):131-6
pubmed: 11394532
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):623-30
pubmed: 20888136
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nat Rev Clin Oncol. 2017 Nov;14(11):695-707
pubmed: 28675164
Mol Cancer Ther. 2016 Apr;15(4):661-9
pubmed: 26846818